CDC

Encore Wire Reports Fourth Quarter and Full Year 2021 Results

Retrieved on: 
Tuesday, February 15, 2022
Residential Building & Real Estate, Commercial Building & Real Estate, Manufacturing, Construction & Property, Professional Services, Building Systems, Architecture, Steel, Other Construction & Property, Finance, Chemicals, Plastics, Health, Income, GAAP, Company, CDC, Aluminium, Public expenditure, Forward-looking statement, U.S. Securities and Exchange Commission, Central, Security (finance), Efficiency, Safety, Environment, EBITDA, Comex, Copper, Depreciation, Growth, Investment, COVID-19, News, Investor, Animal, Internet service provider, Lithium, Video game, Renewable energy, Bank, Risk management

Encore Wire Corporation (NASDAQ Global Select: WIRE) today announced results for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • Encore Wire Corporation (NASDAQ Global Select: WIRE) today announced results for the fourth quarter and year ended December 31, 2021.
  • Copper unit volume, measured in pounds of copper contained in the wire sold, increased 3.9% in the fourth quarter of 2021 versus the fourth quarter of 2020.
  • Gross profit percentage for the fourth quarter of 2021 was 34.2% compared to 15.4% in the fourth quarter of 2020.
  • Net income for the fourth quarter of 2021 was $141.6 million versus $24.1 million in the fourth quarter of 2020.

Calling Young Innovators: T-Mobile and the T-Mobile Foundation Launch Fourth Changemaker Challenge to Fund Big Ideas

Retrieved on: 
Tuesday, February 15, 2022
Telecommunications, Other Education, Consumer Electronics, Technology, University, Primary, Secondary, Education, Mobile, Wireless, NASDAQ, TMUS, CEO, Foundation, CDC, Metro, Mentorship, LTE, Solution, Freedom, Technology, Mental health, T-Mobile, IRS, Â, UN, Multimedia, Program, Life, FOUR, Video game, Sprint, Ashoka, T-Mobile, T-Mobile Foundation, Ashoka, T-MOBILE, T-MOBILE FOUNDATION, ASHOKA

View the full release here: https://www.businesswire.com/news/home/20220215005822/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220215005822/en/
    Calling Young Innovators: T-Mobile and the T-Mobile Foundation Launch Fourth Changemaker Challenge to Fund Big Ideas (Graphic: Business Wire)
    Now through March 31, 2022, teens ages 13 to 18 located in the U.S. and Puerto Rico with bold ideas for driving digital empowerment, putting equity into action and mobilizing for a thriving planet can enter the Changemaker Challenge online.
  • Including this fourth-year commitment, T-Mobile and the T-Mobile Foundation have invested nearly $2.5 million in the Changemaker Challenge since 2018.
  • The Changemaker Challenge is a chance for young people to unleash their big ideas to drive meaningful change in their communities.
  • "T-Mobile, the T-Mobile Foundation, and Ashoka are working together to ensure every young person can develop this new essential power.

Companion Spine LLC Raises $55 Million to Develop and Market Its Innovative Interventional Diagnostic & Surgery solutions for Back Pain

Retrieved on: 
Tuesday, February 15, 2022
Medical Devices, Surgery, Hospitals, Finance, Professional Services, Other Health, Biotechnology, Physical Therapy, Health, Other Professional Services, Health, Degenerative disc disease, Breakthrough, Patient, Surgeon, Food, CEO, Spine, Back pain, VB, CDC, DISC, Pain management, Low back pain, Lumbar spinal stenosis, Solution, IPO, Regulation of tobacco by the U.S. Food and Drug Administration, Factor X, Technology, Pain, Spinal fusion, FDA, Population, Sale, Acquisition, Companion, Patent, Physician, DDD, Diagnosis, LSS, CE, Industry, Pharmaceutical industry, Bookbinding, Medical device, Animal, Medtronic

Companion Spine LLC, the France-USA specialist in diagnostic and interventional spine surgery, announced today that it has raised $55 million.

Key Points: 
  • Companion Spine LLC, the France-USA specialist in diagnostic and interventional spine surgery, announced today that it has raised $55 million.
  • Viscogliosi Brothers initiated and formed Companion Spine to focus on spine pain treatment, motion preservation, precision diagnostics and interventional care to allow for a comprehensive spine health and a total spine care continuum approach for patients, spine pain specialists, treatment centers and payors.
  • Companion Spine's unique positioning, combining early spine pathologies diagnosis with effective, non-invasive, reversible medical solutions and interventional surgery, paves the way for a new way of managing spine pain, allowing patients to avoid heavier and irreversible treatment options such as spine fusion.
  • Companion Spine already has its own subsidiary in the United States to market its medical devices and future diagnostic solutions.

Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) in Adolescents for both the Treatment of Bacterial Vaginosis in Females and Trichomoniasis

Retrieved on: 
Thursday, February 17, 2022
Energy drink, Woman, Propylene glycol, Prevalence, Abdominal pain, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lupinus, Liver failure, Yogurt, Risk, Private Securities Litigation Reform Act, Gaps, Cockayne syndrome, Trichomoniasis, Health, New Drug Application, Vaginitis, Sex, Patient, Bacterial vaginosis, Shanda, Candidiasis, Diarrhea, Female, National Health and Nutrition Examination Survey, Vertically transmitted infection, BV, Patent, Ethanol, Lupin Limited, Sexually transmitted infection, Human, Metronidazole, Headache, Infection, CDC, Incidence, Vomiting, Vaginal yeast infection, National Health, Secnidazole, Reproductive health, Food, Environment, STI, FDA, Prescription, Nausea, Partner (business rank), Dysgeusia, Pharmaceutical industry, Birth control, Legume, Adolescence

"The FDA's approval expands the indication for SOLOSEC to treat adolescents and builds upon our commitment to support women's health.

Key Points: 
  • "The FDA's approval expands the indication for SOLOSEC to treat adolescents and builds upon our commitment to support women's health.
  • Vulvovaginal candidiasis may develop with SOLOSEC and require treatment with an antifungal agent.
  • To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-844-SOLOSEC (1-844-765-6732) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
  • SOLOSEC is a registered trademark of Lupin Inc. and LUPIN is a registered trademark of Lupin Pharmaceuticals, Inc.

AM LLC Announces CDC SHEPheRD Program Selection

Retrieved on: 
Thursday, February 17, 2022
Korea Disease Control and Prevention Agency, Patient, Program, CDC, Contact tracing, Shepherd, Solution, Subclinical infection, Infection, Safety, Technology, IDIQ, Center, Workforce, AM, HAI, Research, Multimedia, COVID-19, Vaccination, LLC, Pharmaceutical industry, Vaccine

The CDC developed the Safety and Healthcare Epidemiology Prevention Research Development (SHEPheRD) Program in 2011.

Key Points: 
  • The CDC developed the Safety and Healthcare Epidemiology Prevention Research Development (SHEPheRD) Program in 2011.
  • AM LLC's contract falls under Domain 3 Formative Research, Guidance Development and Translation to Improve Healthcare Practices.
  • AM LLC was purpose-built to work with partners addressing large-scale public health challenges.
  • AM LLC can design and quickly deploy tailored and scalable workforce solutions to help your organization with all aspects of contact tracing, testing, and vaccine programming.

Board Safely's Virtual Antigen Certification Meets Canada's New Entry Requirement

Retrieved on: 
Wednesday, February 16, 2022
Patient, Food, EUA, COVID, Certification, CDC, Indigenous self-government in Canada, Nursing, COVID-19 testing, Travel, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Board, Government, Severe acute respiratory syndrome coronavirus 2, COVID-19, News, LLC, Vaccine, Medicine

For at-home rapid antigen tests to meet entry requirements, it must be performed and certified by a medical professional, which includes telehealth service.

Key Points: 
  • For at-home rapid antigen tests to meet entry requirements, it must be performed and certified by a medical professional, which includes telehealth service.
  • Board Safely's virtual telehealth platform provides nurse-supervised, rapid antigen COVID test certification quickly, meeting the Canadian government's requirements in an efficient and convenient manner.
  • With Board Safely's virtual, nurse-supervised antigen rapid COVID testing appointments, travelers can be confident they are meeting not only Canada's entry requirements, but the requirements of the U.S. for re-entry."
  • Board Safely , LLC provides virtual, nurse-supervised test certification of SARS-CoV-2 viral tests with Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).

SymCheck® by CLX Health to Provide COVID-19 Health Screening Assessments for the 21st Annual South Beach Wine & Food Festival®

Retrieved on: 
Wednesday, February 16, 2022
Ecosystem, Institute of Cultural Affairs International, Wine, Hospitality, Risk, COVID, CDC, Health, Festival, Food Network, Solution, MIAMI, Impact of the COVID-19 pandemic on the restaurant industry in the United States, Safety, Travel, EEOC, FIU Chaplin School of Hospitality & Tourism Management, Southern Glazer's Wine and Spirits, Student, Capital One, Culture, Global Television Network, COVID-19 testing, Hospital, Laboratory, Wine & Spirits, Physician, HIPAA, Florida International University, Severe acute respiratory syndrome coronavirus 2, COVID-19, Industry, School, Vaccination, Workplace, Nightclub, Broward

In its 21st year, the festival will welcome more than 400 chefs and wine and spirit producers and is expecting over 50,000 attendees.

Key Points: 
  • In its 21st year, the festival will welcome more than 400 chefs and wine and spirit producers and is expecting over 50,000 attendees.
  • As part of the entry requirements for the Festival, all event-goers will complete a digital health screening using SymCheck.
  • "We are proud once again to provide peace of mind together with health safety measures for this prestigious event," said Rick Rasansky, Chief Strategy Officer, SiriusIQ, parent of CLX Health.
  • As part of the entry requirements for SOBEWFF, all attendees must complete a digital health screening through SymCheck.

America's #1 Doctor Trusted Cough & Cold Brand Launches Nationwide Scavenger Hunt

Retrieved on: 
Wednesday, February 16, 2022
Lysol, Health, Queens Center Mall, Enfamil, Veet, Cough, Hygiene, CDC, Air Wick, Nasal congestion, Vaccine, Reckitt, Ibuprofen brand names, Fever, Clearasil, Travel, IHeartRadio, Theatre, Shop, Table, The Shops at North Bridge, Multimedia, IRL, COVID-19, Program, Northbridge, 2000 Goody's Body Pain 500, Life, Online shopping, Calgon, Dettol, Scholl, Vanish, Woolite, Durex, Guaifenesin

This winter, Mucinex, a leading Reckitt health brand, and the #1 doctor trusted cough and cold brand in the U.S. is flipping the script with the launch of the Mucinex Scavenger Hunt,a fun and interactive way for consumers to turn the tables, by playing along and hunting down the cold and flu symptoms.

Key Points: 
  • This winter, Mucinex, a leading Reckitt health brand, and the #1 doctor trusted cough and cold brand in the U.S. is flipping the script with the launch of the Mucinex Scavenger Hunt,a fun and interactive way for consumers to turn the tables, by playing along and hunting down the cold and flu symptoms.
  • This on-the-ground, IRL scavenger hunt is challenging people in New York City, Chicago and Los Angeles to track down the common cold and flu symptoms that Mucinex Fast-Max Cold & Flu All In One relieves.
  • "With the Mucinex Scavenger Hunt, we're reminding consumers they don't need to hunt through the entire cold & flu aisle to find multi-symptom relief, because Fast-Max All In One actually relieves nine common cold & flu symptoms.
  • To bring the scavenger hunt to life, Mucinex partnered with Scavify a free scavenger hunt app that allows participants to join by registering on Scavify.com or by downloading the Scavify app.

The Academy of Oncology Nurse & Patient Navigators Voices Support for Cancer Patient Infusions That Might Enhance Protection Against COVID-19

Retrieved on: 
Wednesday, February 16, 2022
Lynx, Korea Disease Control and Prevention Agency, Patient, Family, Quality of life, Cancer, Food, Health, Risk, CDC, Federation, Academy, Vaccine, RNA transfection, Nursing, Immunodeficiency, Kaiser Family Foundation, Therapy, Oncology, COVID-19 vaccine, Pharmacist, Center, Hematological Cancer Research Investment and Education Act, Treatment, Veni, vidi, vici, MMWR, Pharmacy, FDA, Hospital, Communication, Public health, Disease, Physician, COVID-19, Vaccination, Caregiver, Food and Drug Administration Amendments Act of 2007, Organization, Pharmaceutical industry, Medicine

We are writing you about the special needs of cancer patients and other immune compromised individuals during the COVID-19 pandemic.

Key Points: 
  • We are writing you about the special needs of cancer patients and other immune compromised individuals during the COVID-19 pandemic.
  • Patients with hematologic cancers, many cancer patients in treatment, and certain other cancer patients can offer their experience to underscore the challenges associated with COVID-19.
  • Cancer patients, because of their disease or the treatments for their disease, may be immune compromised.
  • About the Academy of Oncology Nurse & Patient Navigators, Inc. (AONN+)
    The Academy of Oncology Nurse & Patient Navigators, Inc. (AONN+), is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators.

EXERGEN: NEW US FDA STUDY PROVES NON-CONTACT INFRARED THERMOMETERS (NCITs) ARE AN UNRELIABLE TEMPERATURE SCREENING TOOL

Retrieved on: 
Tuesday, February 15, 2022
Scientific Reports, CEO, CDC, NCIT, Nursing, Exergen Corporation, International Committee for Information Technology Standards, Adult, Hariharan, Mother, FDA, Population, Temperature, Fever, Hospital, Marketing, Late preterm infant, Multimedia, Pediatrics, Geriatrics, Dietary supplement

Now, an important new study1 published by the FDA adds to that body of scientific data, demonstrating that non-contact thermometers fail to reliably detect fevers.

Key Points: 
  • Now, an important new study1 published by the FDA adds to that body of scientific data, demonstrating that non-contact thermometers fail to reliably detect fevers.
  • It also proves that they fall outside of the accuracy specifications advertised in manufacturers' instructions and labeling for proper usage.
  • The study was undertaken because of the NCIT's high probability for producing false negative readings close to the CDC fever threshold.
  • It also sought to evaluate their adherence to FDA labeling requirements and in both cases, the non-contact thermometers failed.